Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Eledon Pharmaceuticals (ELDN) Long-Term Deferred Tax (2016)

Eledon Pharmaceuticals filings provide 4 years of Long-Term Deferred Tax readings, the most recent being $65.6 million for Q4 2016.

  • On a quarterly basis, Long-Term Deferred Tax rose 28.64% to $65.6 million in Q4 2016 year-over-year; TTM through Dec 2016 was $65.6 million, a 28.64% increase, with the full-year FY2016 number at $65.6 million, up 28.64% from a year prior.
  • Long-Term Deferred Tax hit $65.6 million in Q4 2016 for Eledon Pharmaceuticals, up from $51.0 million in the prior quarter.
  • In the past five years, Long-Term Deferred Tax ranged from a high of $65.6 million in Q4 2016 to a low of $24.4 million in Q4 2013.
  • Median Long-Term Deferred Tax over the past 4 years was $42.2 million (2014), compared with a mean of $43.6 million.
  • Biggest five-year swings in Long-Term Deferred Tax: skyrocketed 53.37% in 2015 and later rose 28.64% in 2016.
  • Eledon Pharmaceuticals' Long-Term Deferred Tax stood at $24.4 million in 2013, then soared by 36.35% to $33.3 million in 2014, then skyrocketed by 53.37% to $51.0 million in 2015, then increased by 28.64% to $65.6 million in 2016.
  • The last three reported values for Long-Term Deferred Tax were $65.6 million (Q4 2016), $51.0 million (Q4 2015), and $33.3 million (Q4 2014) per Business Quant data.